A marriage of formal methods and LLMs seeks to harness the strengths of both.
RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results